Michael J. Paidas, MD

Professor of Obstetrics, Gynecology, and Reproductive Sciences; Interim Director, Section of Maternal Fetal Medicine; Interim Section Chief, Maternal Fetal Medicine of Yale-New Haven Hospital; Vice Chair, Obstetrics; Program Director, Maternal Fetal Medicine Fellowship; Director of the Yale Women and Children's Center for Blood Disorders and Preeclampsia Advancement; Co-Director, National Hemophilia Foundation - Baxter Clinical Fellowship Program at Yale; Division of Maternal Fetal Medicine

Research Interests

Abruptio Placentae; Pre-Eclampsia; Pregnancy Complications; Pregnancy Complications, Cardiovascular; Pregnancy Complications, Hematologic; Preimplantation Diagnosis; Thrombophilia; Antithrombin III Deficiency; Blood Coagulation Disorders, Inherited; Thrombocytopenia, Neonatal Alloimmune; Diseases

Research Organizations

Obstetrics, Gynecology & Reproductive Sciences: Endometrial Hemostasis/Thrombosis and Angiogenesis Unit | Lipkind Lab (Yale Hearts Moms) | Maternal-Fetal Medicine: Prenatal Genetic Diagnosis Program | Perinatal Research

Faculty Research

Prenatal Laboratory

Office of Cooperative Research

Research Summary

Dr. Paidas's career in medicine has focused on women’s health with special emphasis on blood disorders, reproduction, pregnancy complications and the latter’s impact on health and disease. His activities span direct patient care, translational research and clinical trials. Dr. Paidas’s research has been supported by federal and non- federal funding agencies.

Extensive Research Description

Dr. Paidas’s notable contributions include: description of the regulatory factors of the Protein C system; clinical use of recombinant antithrombin in disease states; elucidation of the subsequent cardiovascular and non-cardiovascular health consequences of hypertensive disorders and preterm delivery in the largest population based studies published to date.

Dr. Paidas and collaborators have described the genomic and proteomic effects of Preimplantation Factor (PIF), a novel mammalian embryo derived factor which regulates maternal receptivity to pregnancy and possesses key immune modulatory properties. Subsequent animal studies using a synthetic analogue of native PIF have shown benefit in animal models related to a variety of immune diseases, including multiple sclerosis and graft versus host disease.

Dr. Paidas is the lead Prinicipal Investigator of a multicenter preeclampsia treatment clinical trial, entitled Prospective Randomized Double-Blind, Placebo Controlled Evaluation of the Pharmacokinetics, Safety and Efficacy of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia (PRESERVE-1).

Dr. Paidas has expertise in prenatal ultrasound, invasive fetal diagnostic and therapeutic procedures. His academic profile includes over 500 published manuscripts, abstracts, books, chapters, presentations or courses.

“Multigate Doppler with Global Acquisition and Signal Processing (G.A.S.P.) in the uteroplacental and fetal circulations.” This new non-invasive Doppler ultrasound technology is being applied to a variety of areas concerning women’s health, including early pregnancy assessment and gynecologic malignancy screening. This project is a collaboration between the Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, Department of Obstetrics and Gynecology; University of Milan, Bicocca, Milan, Italy; Department of Engineering, University of Florence, Florence, Italy; Esaote, Florence, Italy.

“Antithrombin levels preceding placenta mediated complications.” The objective of this study is to determine antithrombin and Preimplantation Factor levels in pregnancy complications, prior to the onset of clinical disease.

“Preimplantation factor (PIF): a biomarker for viable embryo selection after in vitro fertilization and for pregnancy outcome.” This proposal is a multicenter study which investigates the potential role of Preimplantation Factor as a diagnostic test in two settings; namely, to predict IVF success when measured in embryo culture media, and to predict viable pregnancy and a range of placenta mediated complications.

“Predicting Late and Early Perinatal Stroke in High Risk Pregnancies And High Risk Neonates.” The goal is to identify a very high risk population for perinatal stroke suitable for prevention or early treatment.

“Prospective Randomized Double-Blind, Placebo Controlled Evaluation of the Pharmacokinetics, Safety and Efficacy of Recombinant Antithrombin Versus Placebo in Pre-term Pre-eclampsia (PRESERVE-1): RB AT PPE-01-13. Funding Agency: rEVO Biologics (formerly GTC Biotherapeutics). This is a multicenter, randomized, placebo controlled trial to determine whether maternal administration of recombinant antithrombin will prolong gestational age in the setting of preeclampsia at 24 to less than 28 wks.

“Neural Stem Cells and synthetic Preimplantation Factor (sPIF) to treat perinatal brain injury in the rodent. PreImplantation-Factor (PIF) +/- neural stem cells will be investigated as a therapeutic option to treat perinatal brain injury.

Selected Publications

Full List of PubMed Publications

Edit this profile

Contact Info

Michael J. Paidas, MD
Patient Care Locations
Yale Maternal-Fetal Medicine - New LondonLawrence & Memorial Hospital
365 Montauk Avenue

New London, CT 06320
View on map...
Yale Maternal-Fetal Medicine - WaterburyWaterbury Hospital
64 Robbins Street

Waterbury, CT 06708
View on map...
Maternal-Fetal MedicineYale New Haven Hospital
20 York Street, Ste East Pavillion 4th floor

New Haven, CT 06510
View on map...
Yale Maternal-Fetal MedicineYale New Haven Hospital Saint Raphael Campus
1450 Chapel Street

New Haven, CT 06511
View on map...
Yale Maternal-Fetal Medicine Center1 Long Wharf Drive, Ste 2nd Floor
New Haven, CT 06511
View on map...
Mailing Address
Obstetrics, Gynecology & Reproductive SciencesPO Box 208063
New Haven, CT 06520-8063